Executive Director, Evidence Generation and Scientific Communications

Neurogene Inc.; New York (NY); Remote; USD 150,000 - 200,000; Full time

Job summary

Neurogene Inc. is seeking an Executive Director, Evidence Generation and Scientific Communications to lead the comprehensive evidence strategy for NGN-401 and the broader pipeline.

This role partners with Clinical Development, Biostatistics, Regulatory, HEOR/Market Access and field medical to identify evidence gaps and transform them into a prioritized plan, guiding publications, congress activities, and scientific communications. Rare disease and gene therapy experience is highly valued.

Qualifications

• Experience leading evidence generation programs in rare diseases or gene therapy.
• Strong publication and congress strategy experience.
• Ability to translate scientific data into actionable plans.

Responsibilities

• Lead development of the integrated Medical Affairs evidence generation plan for NGN-401 and pipeline programs.
• Collaborate with external experts, investigators, and cross-functional partners (including Clinical Development, Biostatistics, Regulatory, HEOR/Market Access, and Field Medical) to understand the evidence needs of the scientific and clinical community.
• Identify and prioritize key evidence gaps across the needs of clinicians, multidisciplinary care teams, patients, caregivers, and payers.
• Translate evidence gaps into a clear, prioritized roadmap based on scientific impact, strategic relevance, feasibility, and resources.
• Partner with stakeholders to execute the plan.

Skills

Medical affairs leadership

Evidence generation

Scientific communication

Cross-functional collaboration

Job description

Company Background

The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile.

Brief Description

Company Background

The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile.

The Company’s novel and proprietary EXACT transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state‑of‑the‑art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. This transformative work is driven by our highly collaborative people who come together each day to bring us closer to achieving our mission.

As an employee of Neurogene, you will be part of building a culture that honors patient and caregiver mindsets and nurtures innovation, creative problem solving and a strong sense of purpose.

Position Overview

• Work Location: Remote with ~25–30% travel
• Reports To (Position): VP, Medical Affairs

Neurogene is seeking a highly collaborative Executive Director, Evidence Generation and Scientific Communications to lead the generation and execution of the comprehensive evidence that will support NGN-401 and our broader pipeline. This is a critical and highly visible role at a pivotal time for the company. This leader will identify the evidence gaps that matter most to clinicians, multidisciplinary care teams, patients, caregivers, and payers, and turn them into a clear, prioritized plan. Working closely with Clinical Development, Biostatistics, Regulatory, HEOR/Market Access, Medical Affairs and leading external experts, this individual will drive that plan from concept through execution. Beyond evidence generation, this leader will oversee execution of our publication and congress plan, and manuscripts, and will serve as a scientific subject matter expert in the Medical, Legal, and Regulatory (MLR) review process, and support broader scientific communication priorities across Medical Affairs. This role offers the opportunity to shape how the data for a potentially transformative gene therapy are generated, interpreted, and shared with the scientific community. We are looking for someone who brings scientific rigor, sound judgment, and the ability to influence across functions. Experience in rare disease, pediatric neurology, genetic medicine, and/or gene therapy is highly valued. We are equally interested in exceptional candidates who have led evidence generation and publication programs in complex specialty or rare disease settings. In rare disease, every data point matters. The quality of the evidence we generate, and how clearly and credibly we communicate it, will directly shape our ability to serve patients and families.

Requirements

Accountabilities and Responsibilities

Evidence Generation Strategy

• Lead development of the integrated Medical Affairs evidence generation plan for NGN-401 and pipeline programs, aligned with medical, clinical development, and corporate priorities.
• Collaborate with external experts, investigators, and cross-functional partners (including Clinical Development, Biostatistics, Regulatory, HEOR/Market Access, and Field Medical) to understand the evidence needs of the scientific and clinical community.
• Identify and prioritize key evidence gaps across the needs of clinicians, multidisciplinary care teams, patients, caregivers, and payers.
• Translate evidence gaps into a clear, prioritized roadmap based on scientific impact, strategic relevance, feasibility, and resources.
• Partner